| 1. |
Plans for EU disease control centre given boost |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1402,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
Compare losartan with β-blockers other than atenolol |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1402,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Reinstitution of cotrimoxazole cost saving for PCP prophylaxis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1402,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Bupropion, nicotine patch best value for smoking withdrawal |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1402,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Insulin plus metformin cost saving vs triple therapy in diabetes |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1402,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Dronedarone maintains sinus rhythm after cardioversion |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1402,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
CJC 1131*may be effective for the treatment of type 2 diabetes mellitus, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1402,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
News from the 18th Annual Meeting of the Associated Professional Sleep Societies (APSS) |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1402,
2003,
Page 10-11
R Simpson,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
Rivastigmine appears to be beneficial in patients with Alzheimer's disease, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1402,
2003,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Etanercept: TNF antagonist effective in ankylosing spondylitis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1402,
2003,
Page 13-14
RM Poole,
Preview
|
|
摘要:
Etanercept ['Enbrel'], a fully human anti-tumour necrosis factor (TNF) receptor, is effective in the treatment of ankylosing spondylitis, according to studies presented at the annual congress of the European League Against Rheumatism (EULAR) [Lisbon, Portugal; June 2003]. Results from a pivotal phase III study showed that treatment with etanercept produced rapid and durable improvements in symptoms, functional status and fatigue in patients with ankylosing spondylitis. Data from other studies presented at the meeting showed that etanercept improved other patient-reported outcomes, including quality of life (QOL).
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
